Lightning Round: I don't want to buy enterprise software right now, says Jim Cramer

Key Concepts

• Orphan drug model
• Home security cameras
• Onshoring/Reshoring
• Collaborative enterprise software
• Epinephrine nasal spray
• Stock offerings

Biomarin (BMRN) and the Orphan Drug Model

• Main Point: The speaker expresses skepticism about the orphan drug model's current effectiveness.
• Argument: While the orphan drug model was successful in the past, it may no longer be as viable.
• Quote: "I am getting tired of the orphan drug model. I just don't think it's working. I think it worked for some time. I don't think it works."

Arlo Technologies (ARLO) - Home Security Cameras

• Main Point: A caller inquires about Arlo Technologies, a company producing home security cameras with a subscription model.
• Details: The caller mentions owning Arlo cameras for five years and notes the stock is near its all-time high.
• Response: The speaker admits unfamiliarity with Arlo and promises to investigate it.
• Companies Mentioned: ADT

Union Pacific (UNP) and the Impact of Onshoring/Reshoring

• Main Point: A caller asks about the potential impact of onshoring/reshoring trends on transportation, specifically Union Pacific.
• Argument: The speaker believes onshoring/reshoring will benefit Union Pacific.
• Perspective: Union Pacific has lagged behind other transportation companies.
• Recommendation: The speaker considers Union Pacific a "buy."
• People Mentioned: Jim Benner

GitLab (GTLB) - Collaborative Enterprise Software

• Main Point: A caller inquires about GitLab, a collaborative software enterprise company.
• Response: The speaker expresses disinterest in collaborative enterprise software stocks at the moment.
• Reasoning: These stocks are considered too expensive.
• Contrast: The speaker mentions liking Oracle (ORCL), but notes it's a data center play.

Act Pharmaceuticals - Epinephrine Nasal Spray

• Main Point: A caller asks about Act Pharmaceuticals, which has developed an epinephrine nasal spray approved by the FDA and EU.
• Details: The nasal spray is an alternative to epinephrine injections for allergic reactions, including for children. The company has international expansion and recent contracts with $145 million upfront payments.
• Response: The speaker likes the company's model and considers it a "great flier."
• Analysis: The speaker believes the technology is valuable and will be acquired.

New Scale

• Main Point: A caller asks about New Scale.
• Response: The speaker believes the stock is currently too high.
• Strategy: The speaker advises waiting for a stock offering before buying.
• Context: The speaker references a negative event with Okelo.

Conclusion

The lightning round covered a diverse range of stocks and industries, from pharmaceuticals and transportation to enterprise software and home security. The speaker offered opinions based on factors like business models, market trends (onshoring), and stock valuations. A recurring theme was caution towards expensive enterprise software and a preference for companies with unique technologies or those poised to benefit from broader economic shifts. The speaker emphasized the importance of waiting for opportune moments, such as stock offerings, before investing in certain companies.